Double Biologic Regimen for Mantle Cell Lymphoma Well-Tolerated

A new study in the New England Journal of Medicine points towards a more tolerable regimen for patients with Mantle Cell Lymphoma.

In this study, researchers enrolled 38 patients with untreated Mantle Cell Lymphoma with a median age of 65 years. All patients had Ann Arbor stage III or IV disease, and 89% had bone marrow involvement.

The regimen involved two biologics, rituximab and lenalidomide.

Rituximab was administered once weekly for the first 4 weeks and then once every other cycle until disease progression.

During the maintenance phase, lenalidomide was given on days one through to 21 of every 28-day cycle while rituximab was given once every 8 weeks.

Treatment was continued for at least 36 cycles, until disease progression, or unacceptable AEs (adverse events).

Among 36 patients available for evaluation, the overall response rate was 92% while the complete response rate was 64%.

"Treatment of patients with Mantle Cell Lymphoma, who are frequently older (median age 65 years) and unsuitable candidates for intensive regimens, remains a clinical challenge," wrote lead author Jia Ruan MD, PhD, of the Meyer Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital in New York City and colleagues. "Our data show that a lower-intensity approach for initial therapy than that usually used in the case of patients with this cancer can be highly active, with durable responses observed in most patients."

Source: MedPage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap